Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
Dwight Nissley
Frank McCormick
NCI/Frederick RAS
initiative endorsement
The NCI/Frederick Ras Initiative is excited to work with the organizers of the Targeting RAS Symposium and look forward to an excellent meeting which will feature international leaders in RAS biology and targeted therapeutics against RAS cancers. The Targeting RAS Symposium now alternates years with the RAS Initiative Symposium and will feature complimentary agendas. We look forward to a fantastic symposium and seeing you in Salamanca this Fall.
8th - 10th October 2025
Targeting RAS Symposium
WELCOME
For decades, RAS oncogenes were considered undruggable, a challenge that seemed overwhelming. However, groundbreaking basic science discoveries eventually dismantled this long-held belief, opening the door to the development of KRAS-specific inhibitors. These pivotal advancements have led to the approval of the first RAS-targeted therapies in recent years, marking a significant milestone in cancer treatment. Since then, an explosion of novel compounds, utilizing distinct mechanisms of action, has brought about a new era of targeted cancer therapies. These advancements not only offer promising novel therapeutic options but also create opportunities to address longstanding biological questions that have troubled the field.
The rapid progress in the RAS research landscape and the evolution of therapeutic strategies demand an ongoing, dynamic exchange of ideas. Now more than ever, it is crucial to foster dialogue among basic researchers, clinicians, industry experts, and patients. Reflecting on the success of our inaugural Targeting RAS meeting in 2023, we are excited to continue this conversation.
We warmly invite you to join us once again in Salamanca, Spain, this October 2025 for the second edition of Targeting RAS: New Avenues and Challenges. This symposium will bring together leaders from across the scientific community to explore the latest advancements and the challenges that lie ahead in the RAS field.
+
250
Renowned
Experts
Experts
30
Enriching
Days
Days
+
400
Insightful talks
Daily program
8th
9th
10th
8:00
Registration
Event/Welcome
8:45
Opening presentation / Welcome speech
Xosé Bustelo
SESSION 1: RAS signaling
CHAIR: Xosé Bustelo
9:00
SESSION 1
Mechanistic insights into resistance and therapeutic opportunities
Piro Lito
Memorial Sloan Kettering Cancer Center, New York, USA
9:30
SESSION 1
A reference map of the ERK interactome
Georg Vucak
Max Perutz Labs, University of Vienna, Vienna BioCenter, Vienna, Austria
10:00
SESSION 1
Developing combinatorial therapies for RAS pathway driven cancers
Karen Cichowski
Brigham & Women’s Hospital, Harvard Medical School, Boston, USA
10:30
SESSION 1
How SHP2 Signals to RAS
Short talk selected from abstracts
Benjamin neel
NYU Grossman School of Medicine, New York, USA
10:45 – 11:15
COFFEE BREAK
SESSION 2: Unveiling RAS biology
CHAIR: Matthias Drosten
11:15
SESSION 2
Resistance mechanisms to RAS inhibitor treatment in pancreatic cancer
Christine Sers
Charité, Berlin, Germany
11:45
SESSION 2
KRAS mutant isoform-specific vulnerabilities in non-small-cell lung cancer
Angeliki Malliri
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
12:15
SESSION 2
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Driven Melanoma
MARTIN McMAHON
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
12:45
SESSION 2
KRAS blockade elicits a DNA damage repair deficiency exploitable with PARP inhibitors.
Short talk selected from abstracts
Gabriela Novoa
CIMA
13:00 – 15:00
LUNCH & POSTER SESSION
SESSION 3: Decoding RAS-Driven tumours
CHAIR: Esther Castellano
15:00
SESSION 3
Oncogenic RAS activity is associated with immune priming in lung adenocarcinoma
Sophie de Carné
Institut Gustave Roussy, Villejuif, France
15:30
SESSION 3
Targeting RAS in pancreatic cancer
Andy Aguirre
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
16:00
SESSION 3
Mechanisms of tissue tropism for oncogenic K-RAS
Kevin Haigis
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
16:30
SESSION 3
Isoform-specific regulation of KRAS signaling and lysosomal function by RAP1GDS1-607 in lung adenocarcinoma.
Short talk selected from abstracts
Marta román
University of California, San Francisco, USA
16:45 – 17:15
COFFEE BREAK
SESSION 4: Building a Collaborative
European Strategy on RAS (Round table)
17:15 – 18:00
SESSION 4
Round table
Moderator – Javier Carmona
VHIO, Barcelona, Spain
René Bernards
NKI, Amsterdam, The Netherlands
Alberto Bardelli
Scientific Director, IFOM, The AIRC Institute of Molecular Oncology, Milano, Italy
Chiara Ambrogio
University of Turin, Turin, Italy
Silve Vicent
CIMA, Pamplona, Spain
Dwight Nissley
Frederick National Laboratory for Cancer Research (NIH), Frederick, USA
Andy Aguirre
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
END OF DAY 1
SESSION 5: RAS therapies (Clinical perspective)
CHAIR: Colin Lindsay
9:00
SESSION 5
TBD
Jayesh Desai
PETER MAcCALLUM CANCER CENTRE, MELBOURNE, AUSTRALIA
9:25
SESSION 5
TBD
Jarushka Naidoo
Beaumont RCSI Cancer Centre, Dublin, Ireland
9:50
SESSION 5
3D genomic analysis reveals frequent KRAS mutations in multifocal pancreatic precancers
Laura Wood
John Hopkins University School of Medicine, Baltimore, USA
10:15
SESSION 5
The D’s V’s and pan(K)’s: tackling KRASnonG12C driven NSCLC
Jia Luo
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
10:40
SESSION 5
RAS inhibitors combinations including Immunotherapy
Francesco Passiglia
Department of Oncology – University of Turin – San Luigi hospital , Orbassano (TO) – Italy
11:00 – 11:30
COFFEE BREAK
SESSION 6: Emerging treatments (Preclinical perspective)
CHAIR: David Santamaría
11:30
SESSION 6
Targeting K-Ras Using Mutant Selective Covalent Chemistry
Kevan Shokat
University of California, San Francisco, USA
12:00
SESSION 6
Targeting KRAS Using PROTAC Degraders
Kirsten Mcaulay
University of Dundee, Dundee, UK
12:30
SESSION 6
Allosteric nanobodies to study the interactions between SOS1 and RAS
Jan Steyaert
VIB-VUB Center for Structural Biology, VIB & Vrije Universiteit Brussel, Brussels, Belgium
13:00
SESSION 6
VS-7375 (GFH375): An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors
Short talk selected from abstracts
Jonathan Pachter
Verastem Oncology, US
13:15 – 15:00
LUNCH & POSTER SESSION
SESSION 7: Treatments to come (Industry perspective)
CHAIR: Chiara Ambrogio
15:00
SESSION 7
Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors
Jan Smith
Revolution medicines, USA
15:30
SESSION 7
Blocking effector binding to optimize inhibition of RAS-driven MAPK and AKT signaling in cancer
Pedro Beltrán
BridgeBio Oncology Therapeutics
16:00
SESSION 7
Advancing Mutant KRAS Cancer Treatment with Rational Combinations
Carla Martins
AstraZeneca, UK
16:30
SESSION 7
Targeting KRAS and the emergence of resistance
Mark Pearson
Boehringer Ingelheim, Germany
Targeting RAS poster awards
courtesy of 
17:00 – 17:30
COFFEE BREAK
SESSION 8: Treatments & combinations to come
(Round table)
17:30 – 18:15
SESSION 8
Round table
Moderator – Colin Lindsay
University of Manchester and the Christie NHS Foundation Trust, Manchester, UK
Ernest Nadal
Catalan Institute of Oncology, L’Hospitalet, Spain
Jia Luo
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
Kevan Shokat
University of California, San Francisco, USA
Jayesh Desai
PETER MAcCALLUM CANCER CENTRE, MELBOURNE, AUSTRALIA
Terri Coneran
KRAS Kickers, USA
END OF DAY 2
20:30
Place: Cvm Lavde
MEETING DINNER | Cocktail dinner
SESSION 9: Tumor microenvironment
CHAIR: Miriam Molina-Arcas
9:00
SESSION 9
Targeting the interplay between oncogenic RAS signaling and tumour immune evasion in lung cancer
Julian Downward
Francis Crick Institute, London, UK
9:30
SESSION 9
Unmasking contextual determinants of KRAS-driven pancreatic tumorigenesis
Direna Alonso
IRB, Barcelona, Spain
10:00
SESSION 9
From Stroma to Strategy: Uncovering Liabilities in CAF–ECM–Tumor Crosstalk in KRAS-Driven Lung Tumors
Esther Castellano
IBMCC-CIC, Salamanca, Spain
10:30
SESSION 9
Targeting hyaluronic acid in pancreatic ductal adenocarcinoma uncovers novel therapeutic opportunities
Short talk selected from abstracts
Pian Sun
Spanish National Cancer Research Centre (CNIO), spain
10:45 – 11:15
COFFEE BREAK
SESSION 10: Tumour heterogeneity: naïve & post-treatment
CHAIR: Silve Vicent
11:15
SESSION 10
The EGFR as a Master Regulator of Transcriptional and Metabolic Rewiring in RAS mutant Colorectal Cancer
Maria Sibilia
Medical University of Vienna, Vienna, Austria
11:45
SESSION 10
Cell state transitions driving resistance to KRAS inhibition
Tuomas Tammela
Memorial Sloan Kettering Cancer Center, New York, USA
12:15
SESSION 10
Oncogene-induced senescence and tumour initiation
Masashi Narita
Cancer Research UK, Cambridge, UK
12:45
SESSION 10
RAS GTPases Degradation via LZTR1
Dhirendra Simanshu
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
13:15
SESSION 10
Oncogenic KRAS activation induces CRC epithelial plasticity leading to therapeutic resistance in vivo
Short talk selected from abstracts
Andrew Campbell
CRUK Scotland Institute, Scotland
SESSION 11: Closing lecture
CHAIR: Silve Vicent
13:30
SESSION 11
Regulation of MAPK and PI 3′ kinase by RRAS2
FRANK McCORMICK
University of California, San Francisco, USA
END OF DAY 3
END OF THE SYMPOSIUM
Symposium registration
150* / 250€
Students and Postdocs
*Early Bird – From February 7th to August 31st.
Symposium registration
250* / 350€
Nonprofit / Academia
*Early Bird – From February 7th to August 31st.
Symposium registration
500* / 750€
Industry
*Early Bird – From February 7th to August 31st.
Symposium dinner
50€
Join us for an evening of scientific dialogue and networking in a more relaxed setting. The Symposium Dinner, taking place on October 9th at 20:30, offers a unique opportunity to engage with colleagues, speakers, and industry experts in an informal yet stimulating atmosphere at CVM Laude.